Trial Profile
A European randomised multicentre study of interferon alpha-2b versus no treatment after intensive therapy and autologous hematopoeitic stem cell transplantation (ASCT) for relapsing lymphoma patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2010
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 19 Feb 2006 New trial record.